Newsroom

08

February 2017

Wednesday

iX Biopharma Ltd. has reported results for the second financial quarter ended 31 December 2016 (unaudited).

More information can be found in the attached press release. The first quarter financial statements for the period can be found here.

 

21

November 2016

Monday

Homegrown specialty pharmaceutical company iX Biopharma Ltd. is pleased to announce that it has been granted a patent in South Africa for its WaferiX™ drug delivery technology.

More information can be found in the attached press release.

11

November 2016

Friday

iX Biopharma Ltd. has reported results for the first financial quarter ended 30 September 2016 (unaudited).

More information can be found in the attached press release. The first quarter financial statements for the period can be found here.

31

October 2016

Monday

Homegrown specialty pharmaceutical company iX Biopharma Ltd. is pleased to announce that it has been granted a patent in Canada for its WaferiX™ drug delivery technology.

More information can be found in the attached press release.

13

September 2016

Tuesday

iX Biopharma Ltd. is pleased to announce the positive results of a pivotal bioequivalence study comparing iX Biopharma’s novel sildenafil wafer (PheoniX) with the reference drug.

More information can be found in the attached press release.

25

August 2016

Thursday

 iX Biopharma Ltd. has reported results for the fourth financial quarter and full year ended 30 June 2016 (unaudited).

More information can be found in the attached press release. The fourth quarter financial statements for the period can be found here.

 

17

August 2016

Wednesday

iX Biopharma Ltd. has completed pre-clinical development for WafeRest, a sublingual melatonin wafer supplement aimed to alleviate jet lag and improve sleep quality.

More information can be found in the attached press release.

10

August 2016

Wednesday

Homegrown specialty pharmaceutical company iX Biopharma Ltd. has completed preclinical development for BnoX, a sublingual buprenorphine wafer for acute and severe pain management.

More information can be found in the attached press release.

09

June 2016

Thursday

Homegrown specialty pharmaceutical company iX Biopharma Ltd. is pleased to announce that it has been granted a patent in South Korea for its WaferiX™ drug delivery technology.

More information can be found in the attached press release.

27

May 2016

Friday

The board of directors of iX Biopharma Ltd wishes to announce that the Company is proposing to undertake a renounceable non-underwritten rights issue of up to 24,584,284 new ordinary shares in the capital of the Company.

More information can be found in the attached
company announcement on SGX.

For all company announcements, please refer to SGX company disclosures page.

Contact us

iX Biopharma Ltd

1 Kim Seng Promenade
#14-01 Great World City East Tower
Singapore 237994
T: +65 6235 2270
F: +65 6235 2170
E: info@ixbiopharma.com